Chest
CorrespondenceThe Dilemma of Albuterol Dosing for Acute Asthma Exacerbations in Pediatric Patients
Section snippets
To the Editor
Inhaled albuterol is a first-line treatment of acute asthma exacerbations. Nebulized albuterol doses recommended by expert consensus guidelines for exacerbations in children ≤ 12 years of age are “0.15-0.3 mg/kg up to 10 mg every 1-4 hours as needed, or 0.5 mg/kg/hour by continuous nebulization.”1 Although the benefit of continuous treatment is well established, we can find only one, small randomized controlled trial (N = 33) that compared the recommended guideline continuous nebulized
References (4)
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma
(2007)- et al.
Continuous versus intermittent beta-agonists in the treatment of acute asthma
Cochrane Database Syst Rev
(2003)
Cited by (7)
Association of various weight-based doses of continuous albuterol on hospital length of stay
2021, Journal of AsthmaManagement of status asthmaticus in critically ill children
2018, Pediatric Critical Care: Current ControversiesEvaluation of a high-dose continuous albuterol protocol for treatment of pediatric asthma in the emergency department
2013, Pediatric Emergency Care
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Moore served in the speaker's bureau for Merck from July 2008 to June 2009. He also received a research grant from Asklepion Pharmaceuticals for a clinical trial of a medication for asthma. Drs Arnold, Moore, and Hartert currently receive National Institutes of Health support for research grants. Dr Abramo has reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
© 2011 American College of Chest Physicians Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).